Protagenic Therapeutics, Inc. Common Stock News

Protagenic Therapeutics, Inc. (PTIX) Q4 2023 Earnings Call Transcript

Call Scheduled for Monday, April 1st, 2024, at 4:30 pm ET NEW YORK, NY / ACCESSWIRE / March 25, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a biopharmaceutical innovator, announced that the Co

NEW YORK, NY / ACCESSWIRE / October 13, 2023 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders, tod

NEW YORK, NY / ACCESSWIRE / April 26, 2022 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX) a biopharmaceutical company focused on developing drug product candidates to treat stress-related neurologic di

Protagenic Therapeutics Inc (PTIX) shares closed today at 1.5% above its 52 week low of $1.33, giving the company a market cap of $22M. The stock is currently down 2.5% year-to-date, up 134900.0% over the past 12 months, and up 134900.0% over the past five years. This week, the Dow Jones Industrial Average fell 0.9%, and the S&P 500 fell 0.3%. Trading Activity Trading volume this week was 28.0% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and beats it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -34.1% The company's stock price performance over the past 12 months beats the peer average by -430078.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Protagenic Therapeutics Inc (PTIX) shares closed today at 1.5% above its 52 week low of $1.33, giving the company a market cap of $22M. The stock is currently down 2.5% year-to-date, up 134900.0% over the past 12 months, and up 134900.0% over the past five years. This week, the Dow Jones Industrial Average fell 0.9%, and the S&P 500 fell 0.3%. Trading Activity Trading volume this week was 28.0% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 3.0% lower than its 5-day moving average, 8.0% lower than its 20-day moving average, and 24.8% lower than its 90-day moving average. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and beats it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -34.1% The company's stock price performance over the past 12 months beats the peer average by -427753.2% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Protagenic Therapeutics (OTCMKTS: PTIX) is one of 219 public companies in the Business services, not elsewhere classified industry, but how does it compare to its peers? We will compare Protagenic Therapeutics to related businesses based on the strength of its profitability, institutional ownership, dividends, risk, valuation, analyst recommendations and earnings. Institutional & Insider Ownership 1.4% []

Northern Trust Corp purchased a new stake in Protagenic Therapeutics, Inc. (OTCMKTS:PTIX) during the 2nd quarter, Holdings Channel.com reports. The firm purchased 22,485 shares of the biotechnology companys stock, valued at approximately $65,000. Several other institutional investors and hedge funds have also recently added to or reduced their stakes in PTIX. Susquehanna Fundamental Investments LLC []

Protagenic Therapeutics (OTCMKTS: PTIX) is one of 220 public companies in the Business services, not elsewhere classified industry, but how does it compare to its peers? We will compare Protagenic Therapeutics to similar businesses based on the strength of its earnings, valuation, institutional ownership, analyst recommendations, dividends, profitability and risk. Valuation and Earnings This table []

Geode Capital Management LLC acquired a new stake in shares of Protagenic Therapeutics, Inc. (OTCMKTS:PTIX) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 59,083 shares of the biotechnology companys stock, valued at approximately $170,000. Geode Capital Management LLC owned approximately 0.40% of Protagenic []

Protagenic Therapeutics (OTCMKTS: PTIX) is one of 219 public companies in the Business services, not elsewhere classified industry, but how does it contrast to its competitors? We will compare Protagenic Therapeutics to related businesses based on the strength of its analyst recommendations, earnings, valuation, risk, profitability, dividends and institutional ownership. Earnings & Valuation This table []

Squarepoint Ops LLC bought a new stake in shares of Protagenic Therapeutics, Inc. (OTCMKTS:PTIX) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund bought 19,718 shares of the biotechnology companys stock, valued at approximately $57,000. A number of other large investors have also recently made changes to []

Protagenic Therapeutics (OTCMKTS: PTIX) is one of 219 publicly-traded companies in the Business services, not elsewhere classified industry, but how does it weigh in compared to its competitors? We will compare Protagenic Therapeutics to related businesses based on the strength of its risk, earnings, profitability, dividends, analyst recommendations, valuation and institutional ownership. Insider & Institutional [] The post Financial Comparison: Protagenic Therapeutics (PTIX) & Its Peers appeared first on ETF Daily News .

Protagenic Therapeutics (OTCMKTS: PTIX) is one of 219 publicly-traded companies in the Business services, not elsewhere classified industry, but how does it weigh in compared to its rivals? We will compare Protagenic Therapeutics to related companies based on the strength of its earnings, dividends, analyst recommendations, valuation, institutional ownership, risk and profitability. Analyst Ratings This []

Protagenic Therapeutics (OTCMKTS: PTIX) is one of 218 public companies in the Business services, not elsewhere classified industry, but how does it contrast to its competitors? We will compare Protagenic Therapeutics to related businesses based on the strength of its dividends, institutional ownership, earnings, valuation, analyst recommendations, profitability and risk. Valuation & Earnings This table []